Medical cannabis research

Avicanna Reports Q2 2023 Financial Statement

Retrieved on: 
Tuesday, August 15, 2023
GMP, Learning, Medical cannabis research, Global Research Collaboration for Infectious Disease Preparedness, SMA, Natural science, Consortium, Engineering, Bank statement, FSE, Langara College, Research, Stock, Veteran, Capsule, Shoppers Drug Mart, NGC, EBITDA, Acquisition, Patient, Strategy, Cannabis, TSX, Medical cannabis, CCS, Growth, GPP, RHO, Pharmaceutical industry, Drug, Cannabinoid

TORONTO, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company “) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products, is pleased announce the filing of interim financial statements for the three-month period ending June 30, 2023 (“Q2 2023”).

Key Points: 
  • TORONTO, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company “) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products, is pleased announce the filing of interim financial statements for the three-month period ending June 30, 2023 (“Q2 2023”).
  • Medical Cannabis By Shoppers: On May 29, 2023, the Company announced that the definitive Asset Purchase Agreement with Shoppers Drug Mart Inc. for Avicanna to acquire the Medical Cannabis By Shoppers business was fully executed.
  • On May 4, 2023, Avicanna announced the execution of the definitive Master Service Agreement with Northern Green Canada (“NGC”).
  • On May 29, 2023, NGC and Avicanna successfully acquired the inventory for Medical Cannabis by Shoppers and transitioned inventory and fulfilment services to NGC.

Avicanna Provides Corporate Update and Preliminary Q2 Results

Retrieved on: 
Wednesday, June 28, 2023
GMP, Medical cannabis research, Rationalization, FSE, Stock, Capsule, NGC, Patient, Strategy, TSX, Cannabis, Medical cannabis, GPP, Shoppers Drug Mart, Pharmaceutical industry

TORONTO, June 28, 2023 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of plant-derived cannabinoid-based products is pleased to announce a corporate update and preliminary financial results of Q2-2023.

Key Points: 
  • TORONTO, June 28, 2023 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of plant-derived cannabinoid-based products is pleased to announce a corporate update and preliminary financial results of Q2-2023.
  • On May 4, 2023, Avicanna announced the execution of the definitive Master Service Agreement with Northern Green Canada (“NGC”).
  • On May 29, 2023, NGC and Avicanna successfully transitioned the Medical Cannabis by Shoppers inventory and fulfilment services to NGC.
  • Join Avicanna’s management who are providing a corporate update on June 28th at 12 p.m.

Ovation Science Signs Exclusive License Agreement for Its Topical / Transdermal Cannabis Products for Pennsylvania

Retrieved on: 
Wednesday, May 24, 2023
Pennsylvania State University, CSE, Food, Cannabinoid, Research, Ovation, Flax, LAS, Criticism of the Food and Drug Administration, Medical cannabis research, MD, Patient, Cannabis, THC, Skin, Caregiver, Disease, Pharmaceutical industry, CBD

Ovation's products (co-branded as Invibe® MD and Vytal Options) will be sold through these dispensaries and through PA Options' extensive wholesale channels.

Key Points: 
  • Ovation's products (co-branded as Invibe® MD and Vytal Options) will be sold through these dispensaries and through PA Options' extensive wholesale channels.
  • This is Ovation's first licensee in the North East and is part of the Company's strategy to partner with leading US cannabis companies.
  • "Our expansion with PA Options will now establish our products in a market that really needs our science-based products.
  • "We look forward to making Ovation's innovative, science-based products available for medical cannabis patients throughout Pennsylvania" said Tom Trite, CEO of PA Options.

Avicanna Reports Q3 2022 Financial Statement

Retrieved on: 
Monday, November 14, 2022
Transfer, Online, Toronto Stock Exchange, Medical cannabis research, SG, Patent, Dermatology, Growth, SKU, R, Absorption, Offering, Partnership, News, Social media, Research, New England News Collaborative, Incidence, University, Stock, Cannabinoid, Chronic pain, Pain management, FSE, Health, Formulary, Cannabidiol, TSX, Wellness, SEDAR, Neurology, Knowledge, Risk, Q3, Medical cannabis, Administration, RHO, Cannabis, Fine chemical, Pharmaceutical industry, Epilepsy, Seizure

TORONTO, Nov. 14, 2022 (GLOBE NEWSWIRE) -- NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.

Key Points: 
  • TORONTO, Nov. 14, 2022 (GLOBE NEWSWIRE) -- NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.
  • ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS
    TORONTO, November 14, 2022 (GLOBE NEWSWIRE) Avicanna Inc. (Avicanna or the Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on the commercialization of evidence-based, cannabinoid-based products, is pleased to announce the filing of its interim financial statements for the three-month period ending September 30, 2022 (Q3 2022).
  • The process of technical transfer and product re-registrations however, resulted in short term stocking gaps and lower than expected revenues in late Q2 and Q3.
  • Ventures, Inc. for Avicanna to utilize its existing scientific platform and drug delivery systems to develop and commercialize Psilly branded functional fungi-based products.

Revolutionary progress made in the inaugural year of the Panacea Cannabinoid Research Center at Colorado State University

Retrieved on: 
Wednesday, October 26, 2022
Human, Acne, CSU, AD, CBDV, THC, OTCQB, CBC, CRC, Goal, Brain, Dermatitis, Rosacea, Journal, Dog, PTSD, Method, CBE, Gout, Ageing, Post-traumatic stress disorder, Research, Cannabinoid, GLOBE, CBL, Soil, Health, Medical cannabis research, Publication, GMP, Exercise, Maximal and minimal elements, Pesticide, CBG, Government budget balance, Pharmaceutical industry, CBD

GOLDEN, Colo., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Panacea Life Sciences Holdings, Inc. (OTCQB:PLSH) (Panacea or the Company), a Colorado, USA-based cannabinoid research and certified GMP manufacturing company, celebrates its first year of collaboration with Colorado State Universitys Cannabinoid Research Center (CRC).

Key Points: 
  • GOLDEN, Colo., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Panacea Life Sciences Holdings, Inc. (OTCQB:PLSH) (Panacea or the Company), a Colorado, USA-based cannabinoid research and certified GMP manufacturing company, celebrates its first year of collaboration with Colorado State Universitys Cannabinoid Research Center (CRC).
  • With a mission of performing research to solve important industry issues and to better understand how cannabinoids work in the body, the center has made remarkable progress in its inaugural year.
  • Over the last 12 months, the laboratory has been extremely productive through initial analytical research and supporting numerous clinical studies in both dogs and humans.
  • Progress of the CRC will be posted as publications are submitted or clinical studies are completed on both the Colorado State University Panacea Life Sciences Cannabinoid Research Center page and at panacealife.com .

Colorado’s MedPharm Continues to Blaze Path for Cannabis Research in Alzheimer’s Patients

Retrieved on: 
Thursday, July 21, 2022
Science, Biotechnology, Research, Natural Resources, Pharmaceutical, Alternative Medicine, Health, Cannabis, Oxidative stress, Education, NDAS, National, Dementia, NIH, Environment, Neuropharmacology, Center, Pharmacist, United States Department of Health and Human Services, Research, CGMP, Institute, BOLD, Institut français en Inde, Investigational New Drug, ICR, Medical cannabis research, Therapy, Good agricultural practice, Multimedia, Alzheimer's disease, Centers for Disease Control and Prevention, Data analysis, Pharmacology, Inflammation, Human services, MS, Neurological disorder, FDA, GAP, Neurodegeneration, Cannabinoid, American Society for Pharmacology and Experimental Therapeutics, CDC, Bulk, Good manufacturing practice, Cannabis, Population, Medicinal plants, Pharmaceutical industry, CBD, Health

MedPharm Research, a leading cannabis researcher, announced today that the companys proposal, which was submitted to the FY23 Cannabis Research Opportunity at the Colorado State University Institute of Cannabis Research (ICR), titled Isolation and Pharmacological Evaluation of Phytocannabinoids for Alzheimers Disease, has been selected for funding.

Key Points: 
  • MedPharm Research, a leading cannabis researcher, announced today that the companys proposal, which was submitted to the FY23 Cannabis Research Opportunity at the Colorado State University Institute of Cannabis Research (ICR), titled Isolation and Pharmacological Evaluation of Phytocannabinoids for Alzheimers Disease, has been selected for funding.
  • Its by pursuing this one-of-a-kind study in an area where research is really needed that sets MedPharm apart from other cannabis research and development companies, Albert Gutierrez, President of MedPharm, says.
  • MedPharm received the first cannabis research license issued to the state of Colorado in October, 2018.
  • MedPharm Research, a wholly owned subsidiary, also has pending federal application for a Bulk Manufacturing License and has been granted a Schedule I Research license to provide and use cannabis and cannabis dosage forms for research purposes.

DEA Awarding License to Maridose, Bringing International Expertise to Cannabis R&D

Retrieved on: 
Thursday, April 14, 2022
Olam, University, Fraunhofer Society, Federation, Fraunhofer Institute for Solar Energy Systems, Government, Biotechnology, DEA, Research, Center, Science, Brain, Organization, Patient, Conference, Fraunhofer, Reuters, Research design, Cannabis, THC, Medical cannabis research, Institute, Knowledge, Drug, Medicinal plants, Fontainebleau Miami Beach, Tikkun

The field of legalized medical cannabis research and development recently became available for commercial product development and private investment.

Key Points: 
  • The field of legalized medical cannabis research and development recently became available for commercial product development and private investment.
  • One of those companies is Maridose, a collaboration of international cannabis researchers establishing a Center of Excellence for Cannabis Research in Brunswick, Maine.
  • "Conditioned on completion of our facility's construction on April 19th we expect the DEA will issue our final license.
  • Investors can take advantage of significant tax advantages unavailable to cannabis companies in the medical and recreational state marijuana markets.

CannabisWiki Conference & Expo Set to Bring Together Cannabis and Agriculture Industry Leaders and Innovators

Retrieved on: 
Wednesday, March 16, 2022
Health Canada, Association, Twitter, Agriculture, Center, COO, Solution, Education, LinuxWorld Conference and Expo, Patient, Partnership, Conference, Regulatory affairs, WFD, Expo, Problem solving, Medical cannabis research, Agricultural society, Fanshawe College, Research, CEO, Growth, Social media, Industry, Innovation, LinkedIn, Video game, Drug, Indiva, Cannabis, Instagram

London, Ontario--(Newsfile Corp. - March 16, 2022) - Cannabis industry leaders from around Ontario are expected to gather in London, Canada, for the inaugural CannabisWiki Conference & Expo set in South Western Ontario's agricultural epicenter.

Key Points: 
  • London, Ontario--(Newsfile Corp. - March 16, 2022) - Cannabis industry leaders from around Ontario are expected to gather in London, Canada, for the inaugural CannabisWiki Conference & Expo set in South Western Ontario's agricultural epicenter.
  • "Hyde Advisory and CannaNavigators are delighted to be involved in Cannabis Wiki's inaugural Conference and Expo on June 15-16, 2022 in London, ON.
  • The CannabisWiki Conference & Expo is set to forge new relationships and usher in a reinvigorated era for the cannabis & hemp expo space.
  • It strives to be a leader in the Agricultural industry by supporting the agriculture community with programming and facilities that meet the business needs of the sector.

Vyripharm Enterprises, Inc. and Colorado State University Pueblo Announce Sponsored Research and Facilities Agreement

Retrieved on: 
Thursday, March 10, 2022
Seniors, State, Local, Transport, Men, Family, Homeland Security, Training, Elections, Campaigns, Electronic Design Automation, Consumer, Data Management, Public Policy, Government, Technology, Public Relations, Investor Relations, Communications, Nanotechnology, Biotechnology, Alternative Medicine, Supply Chain Management, Health, General Health, Other Philanthropy, Other Science, Research, Wine & Spirits, Logistics, Supply Chain Management, Tobacco, Mobile, Wireless, Food, Beverage, Courts, Law Enforcement, Emergency Services, Retail, Legal, Insurance, Continuing, Fund Raising, Banking, University, Foundation, Science, Professional Services, Education, Philanthropy, Trucking, Women, White House, Federal Government, Cannabis, Compliance, ICR, Texas Medical Center, Research, Public health, Medical cannabis research, Partnership, Colorado State University–Pueblo, CSU, Laboratory, Multimedia, Institute, Infection, Cannabinoid, Science, VEI, Neurology, SRA, Knowledge, Biomedical Research, Enterprise, The Texas Medical Center Library, Certification, Student, Diagnosis, Medicine, Government, Drug, Medical device, TMC, Vyripharm Enterprises, Inc., Colorado State University Pueblo and the Institute of Cannabis Research., VYRIPHARM ENTERPRISES, INC., COLORADO STATE UNIVERSITY PUEBLO AND THE INSTITUTE OF CANNABIS RESEARCH.

Research within the lab will be carried out through the ICR, the nations first multi-disciplinary cannabis research center at a regional, comprehensive institution.

Key Points: 
  • Research within the lab will be carried out through the ICR, the nations first multi-disciplinary cannabis research center at a regional, comprehensive institution.
  • It represents an exceptional opportunity for the Institute and CSU Pueblo to continue advancements in cannabis research and to provide great opportunities for students at CSU Pueblo.
  • About Colorado State University Pueblo and the Institute of Cannabis Research.
  • Colorado State University Pueblo is a fully accredited, regional comprehensive state university that provides social, educational, and cultural opportunities to its constituents.

Avicanna Provides Q4-2021 Results and Corporate Highlights as well as Fiscal 2022 Guidance

Retrieved on: 
Wednesday, February 2, 2022
Growth, Cannabidiol, Absorption, Twitter, Goal, Stock, Offering, Research, Partnership, Risk, GLOBE, FSE, CHF, Medical cannabis research, Lists of diseases, CEO, Medical cannabis, Intellectual, Chronic pain, Prospectus, RHO, Instagram, Company, Q&A, Bulk, United Kingdom, United States Department of Agriculture, SEDAR, Perception, Seed, National Organic Program, Fair Debt Collection Practices Act, News, THC, New, MaRS Discovery District, Dermatology, Solution, EST, Patient, Wellness, Social media, Facebook, Cannabinoid, TSX, National Organ Transplant Act of 1984, API, LinkedIn, Video game, Fine chemical, Drug, Risk management, Pharmaceutical industry, Medical device, CBD, Viola, Q3

Projected total fiscal 2021 revenue of $3.3M, representing a 133% growth from $1.5M in 2020.

Key Points: 
  • Projected total fiscal 2021 revenue of $3.3M, representing a 133% growth from $1.5M in 2020.
  • The Companys international distribution channels also progressed during the quarter with the opening of the Companys 14th international market across four continents.
  • This is further encouraged by the progressive regulations towards medical and pharmaceutical applications of cannabinoid-based products at a global level.
  • On February 3rd, 2022 at 11:00m EST, the Company will be hosting a webinar where CEO, Aras Azadian will be providing further details related to the Q4-21 and 2022 guidance and expectations.